ASLAN PHARMACEU/ADR (NASDAQ:ASLN) has been given an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and three have issued a strong buy recommendation on the company.
Analysts have set a 1 year consensus price objective of $8.88 for the company and are predicting that the company will post ($0.20) earnings per share for the current quarter, according to Zacks. Zacks has also given ASLAN PHARMACEU/ADR an industry rank of 83 out of 256 based on the ratings given to related companies.
ASLN has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating on shares of ASLAN PHARMACEU/ADR in a research report on Thursday, January 24th. Zacks Investment Research cut shares of ASLAN PHARMACEU/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, April 2nd.
ASLAN PHARMACEU/ADR stock traded down $0.10 during mid-day trading on Tuesday, reaching $3.60. The company had a trading volume of 5,554 shares, compared to its average volume of 3,985. ASLAN PHARMACEU/ADR has a fifty-two week low of $2.51 and a fifty-two week high of $10.44. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.64 and a quick ratio of 5.19. The firm has a market capitalization of $115.29 million and a P/E ratio of -2.57.
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last issued its earnings results on Friday, March 22nd. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02. On average, analysts expect that ASLAN PHARMACEU/ADR will post -0.73 earnings per share for the current year.
About ASLAN PHARMACEU/ADR
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Further Reading: Hedge Funds – Risk or Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.